07/09/2021 (Agence Europe) – Although it does not consider an additional dose of Covid-19 vaccine (see EUROPE 12782/22) to be “urgent” for the general population, the European Medicines Agency (EMA) announced, on Monday 6 September, that it will soon make a decision on the use of a third dose of the Pfizer/BioNTech vaccine. The agency says it will review data submitted by the company on the subject, including “the results from an ongoing clinical trial in which around 300 adults with healthy immune systems received a booster dose approximately 6 months after the second dose”. The EMA also states that it has begun to evaluate “the data from the literature” available on the administration of a third dose of messenger RNA vaccines - the BioNTech/Pfizer vaccine and the Moderna vaccine - to severely immunocompromised people. (AC)